Intravitreal Aflibercept for Submacular Hemorrhage
Status:
Completed
Trial end date:
2019-01-20
Target enrollment:
Participant gender:
Summary
The prognosis of exudative age-related macular degeneration (AMD) accompanied by submacular
hemorrhage is generally poor. A recently developed anti-VEGF agent eyeliaTM is also a useful
treatment option for exudative AMD. However, one major limitation of VIEW study was that lack
of data regarding eyes with submacular hemorrhage. The purpose of the present study was to
evaluate the efficacy of Eylea in submacular hemorrhage secondary to exudative AMD.